Godavari Biorefineries launches US biotech arm to advance novel cancer therapies
The move strengthens GBL’s clinical-stage presence in the United States
The move strengthens GBL’s clinical-stage presence in the United States
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
Subscribe To Our Newsletter & Stay Updated